These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27682426)

  • 1. Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus.
    Killikelly AM; Kanekiyo M; Graham BS
    Sci Rep; 2016 Sep; 6():34108. PubMed ID: 27682426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.
    Blais N; Gagné M; Hamuro Y; Rheault P; Boyer M; Steff AM; Baudoux G; Dewar V; Demers J; Ruelle JL; Martin D
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28404847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.
    Swanson KA; Balabanis K; Xie Y; Aggarwal Y; Palomo C; Mas V; Metrick C; Yang H; Shaw CA; Melero JA; Dormitzer PR; Carfi A
    J Virol; 2014 Oct; 88(20):11802-10. PubMed ID: 25078705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.
    Sawada A; Nakayama T
    Microbiol Immunol; 2016 Apr; 60(4):234-42. PubMed ID: 26865035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of calves by a prefusion-stabilized bovine RSV F vaccine.
    Zhang B; Chen L; Silacci C; Thom M; Boyington JC; Druz A; Joyce MG; Guzman E; Kong WP; Lai YT; Stewart-Jones GBE; Tsybovsky Y; Yang Y; Zhou T; Baxa U; Mascola JR; Corti D; Lanzavecchia A; Taylor G; Kwong PD
    NPJ Vaccines; 2017 Mar; 2():7. PubMed ID: 29021918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease.
    Shaw CA; Galarneau JR; Bowenkamp KE; Swanson KA; Palmer GA; Palladino G; Markovits JE; Valiante NM; Dormitzer PR; Otten GR
    Vaccine; 2013 Jan; 31(2):306-12. PubMed ID: 23153444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.
    Johnson TR; Varga SM; Braciale TJ; Graham BS
    J Virol; 2004 Aug; 78(16):8753-60. PubMed ID: 15280483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity.
    Patel N; Tian JH; Flores R; Jacobson K; Walker M; Portnoff A; Gueber-Xabier M; Massare MJ; Glenn G; Ellingsworth L; Smith G
    Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33066540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.
    Johnson TR; Teng MN; Collins PL; Graham BS
    J Virol; 2004 Jun; 78(11):6024-32. PubMed ID: 15141000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics.
    Widjaja I; Rigter A; Jacobino S; van Kuppeveld FJ; Leenhouts K; Palomo C; Melero JA; Leusen JH; Haijema BJ; Rottier PJ; de Haan CA
    PLoS One; 2015; 10(6):e0130829. PubMed ID: 26107504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.
    Espeseth AS; Cejas PJ; Citron MP; Wang D; DiStefano DJ; Callahan C; Donnell GO; Galli JD; Swoyer R; Touch S; Wen Z; Antonello J; Zhang L; Flynn JA; Cox KS; Freed DC; Vora KA; Bahl K; Latham AH; Smith JS; Gindy ME; Ciaramella G; Hazuda D; Shaw CA; Bett AJ
    NPJ Vaccines; 2020; 5(1):16. PubMed ID: 32128257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
    van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
    J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B.
    Joyce MG; Bao A; Chen M; Georgiev IS; Ou L; Bylund T; Druz A; Kong WP; Peng D; Rundlet EJ; Van Galen JG; Wang S; Yang Y; Zhang B; Chuang GY; McLellan JS; Graham BS; Mascola JR; Kwong PD
    Pathog Immun; 2019; 4(2):294-323. PubMed ID: 31893251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice.
    van der Fits L; Bolder R; Heemskerk-van der Meer M; Drijver J; van Polanen Y; Serroyen J; Langedijk JPM; Schuitemaker H; Saeland E; Zahn R
    NPJ Vaccines; 2020; 5(1):49. PubMed ID: 32566260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Jung YJ; Lee Y; Lee JS; Lee YN; Park S; Kang SM
    PLoS One; 2015; 10(10):e0139916. PubMed ID: 26468884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.